NCT02131025: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen |
|
|
| Active, not recruiting | 3 | 428 | US, Canada | ABC/DTG/3TC FDC, Ongoing cART regimen | ViiV Healthcare, PPD, GlaxoSmithKline | Infection, Human Immunodeficiency Virus | 04/15 | 10/15 | | |
NCT02349984: Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer |
|
|
| Recruiting | 2/3 | 105 | RoW | Recombinant anti-tumor and anti-virus protein for injection, Novaferon, Saline Injection, Brand name: Novaferon | Beijing Genova Biotech Company, Ltd. | Metastatic Colorectal Cancer | 05/15 | 05/15 | | |
